E-viri
Recenzirano
-
Chong, Chia-Yin; Kam, Kai-Qian; Zhang, Jinyan; Bertoletti, Antonio; Hariharaputran, Smrithi; Sultana, Rehena; Piragasam, Rupini; Mah, Yun-Yan; Tan, Chee-Wah; Wang, Linfa; Yung, Chee-Fu
Vaccine, 04/2024, Letnik: 42, Številka: 12Journal Article
Heterologous Sinovac-CoronaVac booster(s) in 12–17-year-olds who had a moderate/severe reaction to Pfizer-BNT162b2 mRNA vaccine was found to safe with no serious adverse events reported. In those primed with 1 dose of Pfizer-BNT162b2 vaccine, subsequent boosters with 2 doses of Sinovac-CoronaVac vaccines achieved neutralizing antibody levels which were comparable to those who had received 2 doses of Pfizer-BNT162b2 vaccines followed by 1 dose of Sinovac-CoronaVac vaccination. Adolescents with 1 Pfizer-BNT162b2 followed by 2 Sinovac-CoronaVac vaccines developed T-cell responses against broad peptides including membrane, nucleoprotein 1 and 2 but levels were highest for Spike protein and lasted until day 150 post-vaccination.
